
Larisa H Cavallari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5833904/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet, The, 2013, 382, 790-796.	13.7	237
2	Multisite Investigation of Outcomes WithÂImplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	2.9	213
3	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 2021, 110, 888-896.	4.7	212
4	The IGNITE network: a model for genomic medicine implementation and research. BMC Medical Genomics, 2015, 9, 1.	1.5	189
5	Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood, 2008, 112, 1013-1021.	1.4	187
6	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing. Clinical Pharmacology and Therapeutics, 2021, 109, 1417-1423.	4.7	157
7	Warfarin pharmacogenetics. Trends in Cardiovascular Medicine, 2015, 25, 33-41.	4.9	128
8	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clinical Pharmacology and Therapeutics, 2018, 103, 778-786.	4.7	110
9	Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. BMC Medical Genomics, 2017, 10, 35.	1.5	99
10	CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genetics in Medicine, 2019, 21, 1842-1850.	2.4	96
11	Multisite Investigation of Strategies for the Implementation of <i>CYP2C19</i> Genotypeâ€Guided Antiplatelet Therapy. Clinical Pharmacology and Therapeutics, 2018, 104, 664-674.	4.7	94
12	Recommendations for Clinical CYP2C9 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2019, 21, 746-755.	2.8	84
13	Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenetics and Genomics, 2015, 25, 73-81.	1.5	79
14	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967.	2.2	79
15	Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy, 2017, 37, 1150-1163.	2.6	77
16	Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now. Pharmaceutical Research, 2017, 34, 1551-1555.	3.5	74
17	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2021, 23, 1047-1064.	2.8	73
18	Factors influencing warfarin dose requirements in African–Americans. Pharmacogenomics, 2007, 8, 1535-1544.	1.3	72

#	Article	IF	CITATIONS
19	PharmVar GeneFocus: <i>CYP2C19</i> . Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	4.7	72
20	Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics Service. Pharmacotherapy, 2013, 33, 1156-1164.	2.6	70
21	Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics, 2017, 18, 421-426.	1.3	64
22	Effect of <i>NQO1</i> and <i>CYP4F2</i> genotypes on warfarin dose requirements in Hispanic–Americans and African–Americans. Pharmacogenomics, 2012, 13, 1925-1935.	1.3	59
23	Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood, 2014, 124, 2298-2305.	1.4	57
24	Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Review of Clinical Pharmacology, 2018, 11, 151-164.	3.1	57
25	The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiology, 2012, 8, 563-576.	1.2	56
26	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genetics in Medicine, 2019, 21, 2255-2263.	2.4	53
27	Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings. Genetics in Medicine, 2019, 21, 2264-2274.	2.4	50
28	Pharmacogenetics to guide cardiovascular drug therapy. Nature Reviews Cardiology, 2021, 18, 649-665.	13.7	49
29	Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants. Pharmacotherapy, 2011, 31, 1192-1207.	2.6	45
30	Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course. American Journal of Pharmaceutical Education, 2016, 80, 122.	2.1	43
31	Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults. Clinical Pharmacology and Therapeutics, 2018, 104, 957-965.	4.7	43
32	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. Journal of Translational Medicine, 2018, 16, 92.	4.4	41
33	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. Genetics in Medicine, 2020, 22, 160-169.	2.4	41
34	Genetic Factors Influencing Warfarin Dose in Blackâ€African Patients: A Systematic Review and Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2020, 107, 1420-1433.	4.7	40
35	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	2.8	39
36	How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. Clinical Pharmacology and Therapeutics, 2021, 110, 677-687.	4.7	39

#	Article	IF	CITATIONS
37	Novel genetic predictors of venous thromboembolism risk in African Americans. Blood, 2016, 127, 1923-1929.	1.4	38
38	Pharmacogenomics of Warfarin dose requirements in Hispanicsâ~†. Blood Cells, Molecules, and Diseases, 2011, 46, 147-150.	1.4	36
39	Association of the HLA-B alleles with carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. Pharmacogenomics, 2017, 18, 1643-1648.	1.3	36
40	Opportunity for Genotypeâ€Guided Prescribing Among Adult Patients in 11 US Health Systems. Clinical Pharmacology and Therapeutics, 2021, 110, 179-188.	4.7	35
41	Implementation of inpatient models of pharmacogenetics programs. American Journal of Health-System Pharmacy, 2016, 73, 1944-1954.	1.0	34
42	PharmVar GeneFocus: <i>CYP2C9</i> . Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	4.7	34
43	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Network Open, 2020, 3, e2029411.	5.9	34
44	Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure. Circulation: Heart Failure, 2013, 6, 970-976.	3.9	33
45	Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned. Clinical and Translational Science, 2018, 11, 175-181.	3.1	32
46	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	2.4	32
47	Warfarin pharmacogenomics. Current Opinion in Molecular Therapeutics, 2009, 11, 243-51.	2.8	32
48	Moving Pharmacogenetics Into Practice: It's All About the Evidence!. Clinical Pharmacology and Therapeutics, 2021, 110, 649-661.	4.7	31
49	Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic. Journal of Clinical Medicine, 2020, 9, 2274.	2.4	29
50	Association of Aldosterone Concentration and Mineralocorticoid Receptor Genotype with Potassium Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy, 2010, 30, 1-9.	2.6	28
51	Sex Difference in the Antiplatelet Effect of Aspirin in Patients with Stroke. Annals of Pharmacotherapy, 2006, 40, 812-817.	1.9	27
52	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology, 2021, 14, 963-978.	3.1	27
53	Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent. JAMA - Journal of the American Medical Association, 2018, 320, 1670.	7.4	25
54	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics Journal, 2020, 20, 724-735.	2.0	25

#	Article	IF	CITATIONS
55	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	4.7	25
56	How to Transition from Singleâ€Gene Pharmacogenetic Testing to Preemptive Panelâ€Based Testing: A Tutorial. Clinical Pharmacology and Therapeutics, 2020, 108, 557-565.	4.7	24
57	<i>CYP2C19</i> Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. Journal of the American Heart Association, 2022, 11, e024159.	3.7	24
58	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
59	Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Innerâ€City Population. Pharmacotherapy, 2018, 38, 205-216.	2.6	21
60	Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmacogenomics and Personalized Medicine, 2011, 4, 123.	0.7	20
61	Clinical application of pharmacogenetics in pain management. Personalized Medicine, 2018, 15, 117-126.	1.5	20
62	CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenetics and Genomics, 2013, 23, 228-231.	1.5	19
63	Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients. Pharmacotherapy, 2011, 31, 785-792.	2.6	18
64	Pharmacogenomics of Hypertension and Heart Disease. Current Hypertension Reports, 2015, 17, 586.	3.5	18
65	A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications. Clinical Pharmacology and Therapeutics, 2020, 108, 116-125.	4.7	17
66	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genetics in Medicine, 2021, 23, 1185-1191.	2.4	17
67	A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. Genetics in Medicine, 2021, 23, 621-628.	2.4	17
68	Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemporary Clinical Trials, 2018, 68, 7-13.	1.8	16
69	Racial Differences in Patients' Potassium Concentrations During Spironolactone Therapy for Heart Failure. Pharmacotherapy, 2004, 24, 750-756.	2.6	15
70	<p>Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network</p> . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 217-226.	0.7	14
71	Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. Journal of Cardiac Failure, 2016, 22, 692-699.	1.7	13
72	Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome. Cardiovascular Drugs and Therapy, 2019, 33, 533-546.	2.6	13

#	Article	IF	CITATIONS
73	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotypeâ€Derived Activity Scores. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 678-685.	2.5	13
74	Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic. Clinical and Translational Science, 2021, 14, 589-598.	3.1	13
75	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clinical and Translational Science, 2022, 15, 371-383.	3.1	13
76	Cardiovascular Pharmacogenomics—Implications for Patients With CKD. Advances in Chronic Kidney Disease, 2016, 23, 82-90.	1.4	12
77	Tailoring Drug Therapy Based on Genotype. Journal of Pharmacy Practice, 2012, 25, 413-416.	1.0	11
78	Genetic Determinants of P2Y12 Inhibitors and Clinical Implications. Interventional Cardiology Clinics, 2017, 6, 141-149.	0.4	11
79	Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine. Public Health Genomics, 2018, 21, 217-227.	1.0	11
80	Racial Differences in Potassium Response to Spironolactone in Heart Failure. Congestive Heart Failure, 2006, 12, 200-205.	2.0	10
81	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. Pulmonary Circulation, 2018, 8, 1-8.	1.7	10
82	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 288-302.	1.0	10
83	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. Frontiers in Pharmacology, 2021, 12, 749786.	3.5	10
84	Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. Pharmacogenetics and Genomics, 2018, 28, 207-213.	1.5	9
85	Clinical Utility of Pharmacogene Panelâ€Based Testing in Patients Undergoing Percutaneous Coronary Intervention. Clinical and Translational Science, 2020, 13, 473-481.	3.1	9
86	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. Genetics in Medicine, 2020, 22, 1898-1902.	2.4	9
87	Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model. Pharmacogenomics Journal, 2021, 21, 476-483.	2.0	9
88	Abstract 11802: Clinical Implementation Of CYP2C19-genotype Guided Antiplatelet Therapy Reduces Cardiovascular Events After PCI. Circulation, 2015, 132, .	1.6	9
89	Time to revisit warfarin pharmacogenetics. Future Cardiology, 2017, 13, 511-513.	1.2	8
90	Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2017, 15, 581-589.	1.5	7

#	Article	IF	CITATIONS
91	Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure. Clinical and Translational Science, 2020, 13, 195-203.	3.1	7
92	Multiâ€site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clinical and Translational Science, 2021, 14, 268-276.	3.1	7
93	Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease. Pharmacogenomics Journal, 2021, 21, 657-663.	2.0	7
94	NR3C2 Genotype is Associated with Response to Spironolactone in Diastolic Heart Failure Patients from the Aldoâ€ÐHF Trial. Pharmacotherapy, 2021, , .	2.6	7
95	Impact of the ABCDâ€GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multiâ€Site, Realâ€World Investigation. Clinical Pharmacology and Therapeutics, 2022, 112, 146-155.	4.7	7
96	Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2008, 9, 146-153.	1.7	6
97	Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Translational Research, 2015, 165, 651-657.	5.0	6
98	Association of Î ² -Blocker Dose with Serum Procollagen Concentrations and Cardiac Response to Spironolactone in Patients with Heart Failure. Pharmacotherapy, 2007, 27, 801-812.	2.6	5
99	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. Advances in Molecular Pathology, 2018, 1, 125-134.	0.4	5
100	Utilizing a Human–Computer Interaction Approach to Evaluate the Design of Current Pharmacogenomics Clinical Decision Support. Journal of Personalized Medicine, 2021, 11, 1227.	2.5	5
101	Pharmacogenetics: A precision medicine approach to combatting the opioid epidemic. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 239-250.	1.0	5
102	Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 191-200.	0.9	4
103	A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty. Future Cardiology, 2019, 15, 251-254.	1.2	4
104	Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implementation Science Communications, 2022, 3, 52.	2.2	4
105	Genes affecting warfarin response—interactive or additive?. Journal of Clinical Pharmacology, 2015, 55, 258-260.	2.0	3
106	A case for genotype-guided pain management. Pharmacogenomics, 2019, 20, 705-708.	1.3	3
107	Pharmacogenetics in Cardiovascular Diseases. , 2019, , 133-179.		3
108	Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. Genetic Testing and Molecular Biomarkers, 2019, 23, 209-214.	0.7	3

#	Article	IF	CITATIONS
109	Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking Î ² -blockers. Pharmacogenomics Journal, 2022, 22, 62-68.	2.0	3
110	β1â€receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery. Clinical and Translational Science, 2022, 15, 619-625.	3.1	3
111	Beta-blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	1.9	2
112	Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects. Frontiers in Genetics, 2021, 12, 701405.	2.3	2
113	Personalized medicine in cardiology: the time for genotype-guided therapy is now. Future Cardiology, 2013, 9, 459-464.	1.2	1
114	Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study. Current Problems in Cardiology, 2021, 46, 100816.	2.4	1
115	Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1069-1080.	0.7	1
116	Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. Pharmacogenomics, 2022, 23, 85-95.	1.3	1
117	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 343-351.	1.0	1
118	A Randomized, Crossâ€over Trial of Metoprolol Succinate Formulations to Evaluate <scp>PK</scp> and <scp>PD</scp> Endpoints for Therapeutic Equivalence. Clinical and Translational Science, 2022, , .	3.1	1
119	Implications of Polymorphisms in the BCKDK and GATAâ€4 Gene Regions on Stable Warfarin Dose in African Americans. Clinical and Translational Science, 2021, 14, 492-496.	3.1	0